Kane Biotech Inc (KNE) - Net Assets
Based on the latest financial reports, Kane Biotech Inc (KNE) has net assets worth CA$-793.37K CAD (≈ $-573.91K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$2.74 Million ≈ $1.98 Million USD) and total liabilities (CA$3.53 Million ≈ $2.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of Kane Biotech Inc for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-793.37K |
| % of Total Assets | -28.95% |
| Annual Growth Rate | N/A |
| 5-Year Change | -251.59% |
| 10-Year Change | -439.25% |
| Growth Volatility | 99.03 |
Kane Biotech Inc - Net Assets Trend (2003–2024)
This chart illustrates how Kane Biotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore KNE asset base for the complete picture of this company's asset base.
Annual Net Assets for Kane Biotech Inc (2003–2024)
The table below shows the annual net assets of Kane Biotech Inc from 2003 to 2024. For live valuation and market cap data, see how much is Kane Biotech Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$-1.63 Million ≈ $-1.18 Million |
+80.63% |
| 2023-12-31 | CA$-8.41 Million ≈ $-6.08 Million |
-103.24% |
| 2022-12-31 | CA$-4.14 Million ≈ $-2.99 Million |
-164.05% |
| 2021-12-31 | CA$-1.57 Million ≈ $-1.13 Million |
-245.80% |
| 2020-12-31 | CA$1.07 Million ≈ $777.45K |
+28.43% |
| 2019-12-31 | CA$836.81K ≈ $605.33K |
+184.97% |
| 2018-12-31 | CA$-984.84K ≈ $-712.42K |
-135.97% |
| 2017-12-31 | CA$2.74 Million ≈ $1.98 Million |
+103.20% |
| 2016-12-31 | CA$1.35 Million ≈ $974.76K |
+180.58% |
| 2015-12-31 | CA$480.25K ≈ $347.40K |
-63.75% |
| 2014-12-31 | CA$1.32 Million ≈ $958.43K |
+3.25% |
| 2013-12-31 | CA$1.28 Million ≈ $928.25K |
-45.35% |
| 2012-12-31 | CA$2.35 Million ≈ $1.70 Million |
-1.26% |
| 2011-12-31 | CA$2.38 Million ≈ $1.72 Million |
+104.37% |
| 2010-12-31 | CA$1.16 Million ≈ $841.74K |
-35.26% |
| 2009-12-31 | CA$1.80 Million ≈ $1.30 Million |
+20.40% |
| 2008-12-31 | CA$1.49 Million ≈ $1.08 Million |
+30.86% |
| 2007-12-31 | CA$1.14 Million ≈ $825.19K |
-19.94% |
| 2006-12-31 | CA$1.42 Million ≈ $1.03 Million |
+40.04% |
| 2005-12-31 | CA$1.02 Million ≈ $735.99K |
+138.47% |
| 2004-12-31 | CA$426.65K ≈ $308.63K |
-55.34% |
| 2003-12-31 | CA$955.27K ≈ $691.03K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kane Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3373521200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$32.79 Million | % |
| Total Equity | CA$-1.63 Million | 100.00% |
Kane Biotech Inc Competitors by Market Cap
The table below lists competitors of Kane Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beston Global Food Company Ltd
AU:BFC
|
$4.24 Million |
|
Kuke Music Holding Ltd
NYSE:KUKE
|
$4.24 Million |
|
PREMIER AFRICAN MINERALS
F:0PA
|
$4.24 Million |
|
Altur Slatina
RO:ALT
|
$4.25 Million |
|
ASTROTECH CORP.
F:SP5
|
$4.24 Million |
|
Gold Basin Resources Corp
V:GXX
|
$4.24 Million |
|
ABM International Limited
NSE:ABMINTLLTD
|
$4.23 Million |
|
ADDvise Group AB A
ST:ADDV-A
|
$4.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kane Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -10,558,304 to -1,629,237, a change of 8,929,067.
- Net income of 6,097,942 contributed positively to equity growth.
- Other comprehensive income decreased equity by 140,600.
- Other factors increased equity by 2,971,725.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$6.10 Million | +374.28% |
| Other Comprehensive Income | CA$-140.60K | -8.63% |
| Other Changes | CA$2.97 Million | +182.4% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Kane Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | CA$0.50 | CA$0.04 | x |
| 2004-12-31 | CA$0.15 | CA$0.04 | x |
| 2005-12-31 | CA$0.31 | CA$0.04 | x |
| 2006-12-31 | CA$0.39 | CA$0.04 | x |
| 2007-12-31 | CA$0.27 | CA$0.04 | x |
| 2008-12-31 | CA$0.27 | CA$0.04 | x |
| 2009-12-31 | CA$0.27 | CA$0.04 | x |
| 2010-12-31 | CA$0.14 | CA$0.04 | x |
| 2011-12-31 | CA$0.19 | CA$0.04 | x |
| 2012-12-31 | CA$0.17 | CA$0.04 | x |
| 2013-12-31 | CA$0.07 | CA$0.04 | x |
| 2014-12-31 | CA$0.07 | CA$0.04 | x |
| 2015-12-31 | CA$0.02 | CA$0.04 | x |
| 2016-12-31 | CA$0.04 | CA$0.04 | x |
| 2017-12-31 | CA$0.04 | CA$0.04 | x |
| 2018-12-31 | CA$-0.01 | CA$0.04 | x |
| 2019-12-31 | CA$0.01 | CA$0.04 | x |
| 2020-12-31 | CA$-0.01 | CA$0.04 | x |
| 2021-12-31 | CA$-0.03 | CA$0.04 | x |
| 2022-12-31 | CA$-0.05 | CA$0.04 | x |
| 2023-12-31 | CA$-0.08 | CA$0.04 | x |
| 2024-12-31 | CA$-0.01 | CA$0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kane Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 293.05%
- • Asset Turnover: 0.83x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-80.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -42.45% | -529.15% | 0.08x | 1.06x | CA$-501.07K |
| 2004 | -141.23% | -4492.04% | 0.03x | 1.23x | CA$-645.23K |
| 2005 | -99.24% | 0.00% | 0.00x | 1.13x | CA$-1.11 Million |
| 2006 | -67.08% | -3966.13% | 0.02x | 1.07x | CA$-1.10 Million |
| 2007 | -95.55% | -6353.20% | 0.01x | 1.08x | CA$-1.20 Million |
| 2008 | -72.14% | 0.00% | 0.00x | 1.05x | CA$-1.23 Million |
| 2009 | -48.81% | 0.00% | 0.00x | 1.04x | CA$-1.06 Million |
| 2010 | -83.64% | 0.00% | 0.00x | 1.08x | CA$-1.09 Million |
| 2011 | -51.35% | 0.00% | 0.00x | 1.04x | CA$-1.46 Million |
| 2012 | -62.16% | 0.00% | 0.00x | 1.08x | CA$-1.69 Million |
| 2013 | -112.79% | -904.91% | 0.08x | 1.47x | CA$-1.58 Million |
| 2014 | -121.89% | -3854.29% | 0.02x | 1.50x | CA$-1.75 Million |
| 2015 | -356.07% | -1634.42% | 0.09x | 2.44x | CA$-1.76 Million |
| 2016 | -189.15% | -1041.34% | 0.11x | 1.58x | CA$-2.68 Million |
| 2017 | -101.76% | -269.12% | 0.30x | 1.24x | CA$-3.06 Million |
| 2018 | 0.00% | -644.12% | 0.33x | 0.00x | CA$-3.16 Million |
| 2019 | -114.74% | -56.70% | 0.61x | 3.29x | CA$-1.04 Million |
| 2020 | 0.00% | -277.04% | 0.27x | 0.00x | CA$-3.57 Million |
| 2021 | 0.00% | -286.39% | 0.26x | 0.00x | CA$-4.22 Million |
| 2022 | 0.00% | -145.78% | 0.47x | 0.00x | CA$-3.24 Million |
| 2023 | 0.00% | -3379.05% | 0.03x | 0.00x | CA$-3.98 Million |
| 2024 | 0.00% | 293.05% | 0.83x | 0.00x | CA$6.26 Million |
Industry Comparison
This section compares Kane Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $24,209,535
- Average return on equity (ROE) among peers: -379.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kane Biotech Inc (KNE) | CA$-793.37K | -42.45% | N/A | $4.24 Million |
| Appili Therapeutics Inc (APLI) | $-13.40 Million | 0.00% | 0.00x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $7.33 Million | -189.11% | 0.18x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $1.06 Million | -79.15% | 0.19x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-1.30 Million | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $1.18 Million | -3177.89% | 21.71x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Helix BioPharma Corp. (HBP) | $-1.39 Million | 0.00% | 0.00x | $116.58 Million |
| Hemostemix Inc (HEM) | $-6.77 Million | 0.00% | 0.00x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $3.94 Million | -266.20% | 0.60x | $1.13 Million |
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the … Read more